EDIT vs TLRY · rev $32.3M vs rev $821.3M
Editas Medicine Inc (EDIT) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported TLRY revenue for 2025-05-31 was $821.3M. Net income was -$2.18B. Revenue was up 4.1% from 2024-05-31 to 2025-05-31. TLRY currently screens at market cap $573.9M.
EDIT currently screens at market cap $375.2M. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the EDIT and TLRY stock pages for the full models.
Not investment advice.